KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Operating Leases (2019 - 2025)

Astrazeneca has reported Operating Leases over the past 7 years, most recently at $1.4 billion for Q4 2025.

  • Quarterly results put Operating Leases at $1.4 billion for Q4 2025, up 27.67% from a year ago — trailing twelve months through Dec 2025 was $1.4 billion (up 27.67% YoY), and the annual figure for FY2025 was $1.4 billion, up 27.67%.
  • Operating Leases for Q4 2025 was $1.4 billion at Astrazeneca, up from $1.1 billion in the prior quarter.
  • Over the last five years, Operating Leases for AZN hit a ceiling of $1.4 billion in Q4 2025 and a floor of $857.0 million in Q4 2023.
  • Median Operating Leases over the past 5 years was $987.0 million (2021), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Operating Leases: skyrocketed 44.93% in 2021 and later fell 10.07% in 2023.
  • Astrazeneca's Operating Leases stood at $987.0 million in 2021, then decreased by 3.44% to $953.0 million in 2022, then dropped by 10.07% to $857.0 million in 2023, then rose by 29.87% to $1.1 billion in 2024, then rose by 27.67% to $1.4 billion in 2025.
  • The last three reported values for Operating Leases were $1.4 billion (Q4 2025), $1.1 billion (Q4 2024), and $857.0 million (Q4 2023) per Business Quant data.